Established in 1998, Aurisco is an innovative pharmaceutical company engaged in research, development, manufacturing and marketing of specialty APIs, formulations as well as CRDMO service. With headquarters in Shanghai, 6 R&D centers and building its 4th cGMP manufacturing site in China, the company has offices in China, USA, Portugal, India and Brazil. Aurisco has been deeply involved in the pharmaceutical industry for more than 25 years and commits itself to continuous technological innovation and sustainability. Having passed 5 cGMP inspections in 2023 (USFDA/EUGMP/PMDA/NMPA/KFDA), Aurisco Pharmaceutical is expanding in terms of capacity with a new site starting operation in 2024, growing its toolbox of technologies, small molecule API offer and unbeatable CRDMO services for oligonucleotides and peptides. Today, the company plays a leading role in China and global markets in the field of complex synthesis, synthetic biology, photochemistry and continuous flow chemistry. Aurisco has become Ecovadis ranked and joined the SBTi with a target of becoming carbon neutral by 2027, reaching zero emissions by 2030, being a reliable long-term partner of the well-known pharmaceutical companies worldwide. Our focus on customer service, mature quality system, regulatory experience, growing production capacity and global sales network enables the company to provide high-quality products and efficient service to our customers around the world.
| API Name | DMF（Drug Mater File） | |
| Abiraterone Acetate | EU,US,CANADA,CHINA,JAPAN, BRAZIL | |
| Apalutamide | Q1 2024 | |
| Bempedoic Acid | EU, US, CHINA | |
| Betamethasone Valerate | EU(CEP), CANADA | |
| Brivaracetam | EU, US, CANADA, CHINA | |
| Budesonide | Q1 2024 | |
| Elagolix | EU, US | |
| Enzalutamide | EU, US, CHINA | |
| Eplerenone | EU(CEP), US, CANADA, JAPAN | |
| Finerenone | Q4 2024 (NCE-1 09 Jul 2025) | |
| Dydrogesterone | EU(CEP), US, CHINA | |
| Fluticasone Propionate | EU(CEP), US, CHINA | |
| Fluticasone Furoate | EU(CEP), US, CHINA | |
| Mometasone Furoate | EU(CEP), US | |
| Nusinersen (ASO, Oligonucleotides) | Q1 2024 | |
| Pregabalin | EU(CEP), US, CANADA, CHINA | |
| Relugolix | Q1, 2024 | |
| TDF (Tenofovir Disoproxil Fumarate) | EU, US, CHINA | |
| TAF (Tenofovir Alafenamide Hemifumarate) | EU, US, CHINA | |
| TMF(Tenofovir Alafenamide Monofumarate) | EU, US, CHINA | |
| Vibegron | Q2 2024 |
